Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01038245 · ClinicalTrials.gov registry record
Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- 72
- Enrollment target
NCT01038245: Completed study, sponsored by National Institute on Drug Abuse (NIDA).
NCT01038245 is a clinical trial that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 72 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01038245 has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- 72 participants
- Enrollment target
Study Summary
Background: \- Central nicotinic acetylcholine receptors (nAChRs) are primary targets for the action of nicotine. In addition to being involved in tobacco dependence, they are also involved in a variety of brain disorders, including Alzheimer's and Parkinson's diseases. Researchers are interested in developing better ways to study the action of nAChRs to improve treatments for smoking cessation and other problems affected by these receptors. These new study methods may involve different approaches to positron emission tomography (PET) scanning, which can show brain activity related to nAChRs. Objectives: \- To evaluate appropriate and useful doses of radiotracers used in PET scanning of nAChRs in the brains of nonsmokers/former smokers, light smokers, and heavy smokers. Eligibility: \- Individuals between 18 and 50 years of age who fall into one of the following groups: (1) nonsmokers or former smokers who have not smoked for the past 2 years, (2) light/situational smokers, or (3) heavy smokers (at least 15 cigarettes/day for the past 2 years). Design: * Each participant will undergo up to three PET studies, given approximately1 month apart. Each study will take approximately 8 hours to complete. * Participants will provide urine and breath samples before the study and at the start of the study, which will be tested for chemicals that may interfere with the study. * Depending on the study, some of the smoking participants may receive a nicotine patch to wear during the PET scan. * On the day of the study, participants will receive a dose of a radiotracer (a drug used in PET scanning) given either as a single injection or as an injection followed by a continuous infusion, and will have a series of PET scans over the next 7 hours and provide blood samples during that time. * Participants will return for a follow-up visit 1 month after the end of the study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2003-07-08 |
| Est. Completion | 2011-11-18 |
What the finished NCT01038245 record still lists
NCT01038245 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01038245 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01038245 about?
NCT01038245 is a clinical study titled "Quantitation of Human Cerebral Nicotinie Receptors With 2[18F]FA-85380 and PET Healthy Non-smokers and Ex-Smokers and in Heavy and Light Situational Smokers". Background: \- Central nicotinic acetylcholine receptors (nAChRs) are primary targets for the action of nicotine. In addition to being involved in tobacco dependence, they are also involved in a variety of brain disorders, including Alzheimer's and Parkinson's diseases. Researchers are interested i...
What is the current status of trial NCT01038245?
This trial is currently completed. The enrollment target is 72 participants. The study started on 2003-07-08. Estimated completion is 2011-11-18.
Who is sponsoring clinical trial NCT01038245?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI